It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Interferon-induced transmembrane proteins (IFITMs 1, 2 and 3) can restrict viral pathogens, but pro- and anti-viral activities have been reported for coronaviruses. Here, we show that artificial overexpression of IFITMs blocks SARS-CoV-2 infection. However, endogenous IFITM expression supports efficient infection of SARS-CoV-2 in human lung cells. Our results indicate that the SARS-CoV-2 Spike protein interacts with IFITMs and hijacks them for efficient viral infection. IFITM proteins were expressed and further induced by interferons in human lung, gut, heart and brain cells. IFITM-derived peptides and targeting antibodies inhibit SARS-CoV-2 entry and replication in human lung cells, cardiomyocytes and gut organoids. Our results show that IFITM proteins are cofactors for efficient SARS-CoV-2 infection of human cell types representing in vivo targets for viral transmission, dissemination and pathogenesis and are potential targets for therapeutic approaches.
IFITM proteins can inhibit several viruses, but effects on SARS-CoV-2 infection are not well understood. Here, the authors show that endogenous IFITMs support SARS-CoV-2 infection in different in vitro models by binding spike and enhancing virus entry.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





















1 Ulm University Medical Center, Institute of Molecular Virology, Ulm, Germany (GRID:grid.410712.1)
2 Ulm University Medical Center, Department of Internal Medicine I, Ulm, Germany (GRID:grid.410712.1)
3 Ulm University Medical Center, Institute of Molecular Virology, Ulm, Germany (GRID:grid.410712.1); King’s College London, Department of Infectious Diseases, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
4 Ulm University, Department of Internal Medicine II (Cardiology), Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)
5 Ulm University Medical Center, Core Facility of Functional Peptidomics, Ulm, Germany (GRID:grid.410712.1); Ulm University Medical Center, Core Unit of Mass Spectrometry and Proteomics, Ulm, Germany (GRID:grid.410712.1)
6 Ulm University Medical Center, Core Unit of Mass Spectrometry and Proteomics, Ulm, Germany (GRID:grid.410712.1)
7 Ulm University Medical Center, Institute of Molecular Virology, Ulm, Germany (GRID:grid.410712.1); University Hospital Tübingen, Institute of Medical Virology and Epidemiology of Viral Diseases, Tübingen, Germany (GRID:grid.411544.1) (ISNI:0000 0001 0196 8249)
8 Charité—Universitätsmedizin Berlin, Institute of Virology, Berlin, Germany (GRID:grid.6363.0) (ISNI:0000 0001 2218 4662)
9 Ulm University, Institute for Anatomy and Cell Biology, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)
10 Ulm University, Institute for Anatomy and Cell Biology, Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748); Ulm University, Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE), Ulm, Germany (GRID:grid.6582.9) (ISNI:0000 0004 1936 9748)
11 Ulm University Medical Center, Institute of Medical Microbiology and Hygiene, Ulm, Germany (GRID:grid.410712.1)
12 The University of Tokyo, Institute of Medical Science, Tokyo, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2151 536X)